Associated tags: Diamond, BRAF, CNS, GBM, EGFR, Brain, RAF, NRAS, Therapy, NSCLC, Patient, Cancer, Pharmaceutical industry, M26 Modular Accessory Shotgun System, Black Diamond, Conference, Lung cancer, FDA
Locations: NEW YORK, CALIFORNIA, BOSTON, NY, CAMBRIDGE, MA, US, BLACK DIAMOND, KRAS
Diamond,
Attention,
Telephone,
Black Diamond,
SEC filing,
Sale,
M26 Modular Accessory Shotgun System,
Patient,
Cancer,
Nicollet Mall,
Security (finance) and NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock.
Key Points:
- and NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock.
- Black Diamond also intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock.
- All of the shares in the proposed offering are to be sold by Black Diamond.
- The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Diamond,
PK,
DNA,
Radiation,
Central nervous system,
PRS,
GBM,
Diarrhea,
Half-life,
Progression-free survival,
RECIST,
Pharmacokinetics,
Black Diamond,
Mutation,
TKI,
Toxicity,
Appetite,
Lung cancer,
Paronychia,
CNS,
Associate,
Glioblastoma,
Rash,
M26 Modular Accessory Shotgun System,
Patient,
Stomatitis,
EGFR,
Memorial Sloan Kettering Cancer Center,
Cancer,
Webcast,
Nausea,
Neoplasm,
FDA,
Therapy,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
ORR,
Food,
Metastasis,
Safety,
Fatigue,
Disease,
Medical imaging,
Pharmaceutical industry,
NSCLC BDTX-1535 is an investigational fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor being developed for the treatment of non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM).
Key Points:
- BDTX-1535 is an investigational fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor being developed for the treatment of non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM).
- The new data from the dose escalation portion of the Phase 1 study demonstrated clinical proof of activity of BDTX-1535 in NSCLC patients harboring both acquired resistance and intrinsic driver EGFR mutations.
- “These initial safety and clinical activity data support the continued development of BDTX-1535 as a potential first and best-in-class treatment option for osimertinib-resistant NSCLC patients.
- ET to discuss the initial results from the Phase 1 dose escalation study of BDTX-1535 in patients with NSCLC.
Diamond,
DevOps,
University,
Senior,
George Washington University School of Medicine & Health Sciences,
Black Diamond,
Genentech,
Lung cancer,
Glioblastoma,
University of California, Davis,
M26 Modular Accessory Shotgun System,
Acquisition,
Patient,
Outline of health sciences,
Cancer,
Medivation,
Pfizer,
Pharmaceutical industry,
Nursing,
Science and NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced the promotion of Melanie Morrison from Senior Vice President, Development Operations to Chief Development Officer.
Key Points:
- and NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced the promotion of Melanie Morrison from Senior Vice President, Development Operations to Chief Development Officer.
- As Chief Development Officer, Ms. Morrison leads the Company’s clinical operations, program management and program leadership functions, and regulatory affairs.
- She has played an integral part in our Phase 1 trial for BDTX-1535 in non-small cell lung cancer and glioblastoma and I am extremely pleased to announce her well-deserved promotion to Chief Development Officer.
- Ms. Morrison joined Black Diamond in October 2022 with over two decades of experience in clinical operations, program management, product leadership and other key development functions in addition to driving corporate transitions from early to late-stage development at several biopharmaceutical companies.
and NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an overview of the Company’s MasterKey programs, including BDTX-1535 and BDTX-4933, at the Jefferies Healthcare Conference on Friday, June 9, 2023, at 12:45 p.m.
Key Points:
- and NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an overview of the Company’s MasterKey programs, including BDTX-1535 and BDTX-4933, at the Jefferies Healthcare Conference on Friday, June 9, 2023, at 12:45 p.m.
- ET in New York, NY.
- A live webcast of the presentation can be accessed by visiting the investors relations section of the Company’s website at: www.blackdiamondtherapeutics.com .
- A replay of the webcast will also be available and archived for 90 days following the event.
Diamond,
FGFR,
MAP,
Myenteric plexus,
Central nervous system,
Anticipation,
GBM,
Pharming,
Neoplasm,
Clinical trial,
Cancer,
MAPK,
Pharmacokinetics,
BRAF,
G&A,
Lung cancer,
CNS,
Drug design,
II,
Glioblastoma,
M26 Modular Accessory Shotgun System,
Development,
Phase 1,
State Administrative Expenses,
Outline,
Investment,
Patient,
RAS,
EGFR,
Administration,
Decompression (diving),
Drug discovery,
Poster,
R,
Research,
FDA,
Therapy,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
IND,
III,
Food,
Safety,
Penetrance,
RAF,
Pharmaceutical industry,
Cryptocurrency,
NSCLC We are confident that our momentum will continue to bring tremendous progress across our pipeline as we head further into this transformational year for Black Diamond,” said David Epstein, Ph.D., President and Chief Executive Officer of Black Diamond Therapeutics.
Key Points:
- We are confident that our momentum will continue to bring tremendous progress across our pipeline as we head further into this transformational year for Black Diamond,” said David Epstein, Ph.D., President and Chief Executive Officer of Black Diamond Therapeutics.
- In April 2023, Black Diamond presented two posters highlighting BDTX-1535’s preclinical development as well as the ongoing Phase 1 clinical trial at the 2023 AACR Annual Meeting.
- Black Diamond remains on track to provide a clinical update on BDTX-1535 in the second half of 2023.
- In the first quarter of 2023, Black Diamond received allowance of its IND application from the U.S. Food and Drug Administration (FDA).
and NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an overview of the Company’s MasterKey programs, including BDTX-1535 and BDTX-4933, at the Stifel 2023 Targeted Oncology Days on Tuesday, April 25, 2023, at 11:00 a.m.
Key Points:
- and NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an overview of the Company’s MasterKey programs, including BDTX-1535 and BDTX-4933, at the Stifel 2023 Targeted Oncology Days on Tuesday, April 25, 2023, at 11:00 a.m.
- ET, being held virtually.
- A live webcast of the presentation can be accessed by visiting the investors relations section of the Company’s website at: www.blackdiamondtherapeutics.com .
- A replay of the webcast will also be available and archived for 90 days following the event.
Diamond,
MAP,
Glioblastoma,
Myenteric plexus,
AACR,
Central nervous system,
Temozolomide,
GBM,
Phosphorylation,
Drug discovery,
Neoplasm,
Cell proliferation,
Cancer,
Pharmacokinetics,
MAPK,
Black Diamond,
BRAF,
Mutation,
Brain,
NSCLC,
Lung cancer,
CNS,
Trial of the century,
II,
M26 Modular Accessory Shotgun System,
Phase 1,
TMZ,
RAS,
Patient,
EGFR,
ERK,
MET,
Decompression (diving),
Chemoradiotherapy,
Assessment,
III,
Safety,
Penetrance,
RAF,
Vaccine,
Pharmaceutical industry,
Medical imaging,
Antibiotics,
Medical device Real world data in GBM demonstrates EGFR alterations often co-occur and persist throughout treatment with current standard of care therapy.
Key Points:
- Real world data in GBM demonstrates EGFR alterations often co-occur and persist throughout treatment with current standard of care therapy.
- Black Diamond remains on track to provide a clinical update on BDTX-1535 in the second half of 2023.
- Black Diamond expects to initiate a Phase 1 clinical trial of BDTX-4933 in patients with tumors harboring all-class BRAF or RAS mutations in the second quarter of 2023.
- The posters from the AACR Annual Meeting are available on the “Scientific Presentations and Publications” section of the Black Diamond Therapeutics website.
Diamond,
Black Diamond,
Glioblastoma,
IND,
BRAF,
Clinical trial,
MAP,
EORTC,
Mutation,
Treatment,
Development,
R,
Neoplasm,
Cancer,
RAF,
Administration,
Research,
Patient,
FDA,
Investigational New Drug,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Lung cancer,
NEA,
RAS,
II,
Food,
Toxic encephalopathy,
Myenteric plexus,
EGFR,
FGFR,
Brain,
Investment,
M26 Modular Accessory Shotgun System,
Drug discovery,
European Organisation for Research and Treatment of Cancer,
III,
NSCLC,
Poster,
GBM,
Pharmaceutical industry,
Cryptocurrency,
Launch pad,
G&A We’ve designed a robust pipeline of products with brain penetration properties to address these key challenges,” said David Epstein, Ph.D., President and Chief Executive Officer of Black Diamond.
Key Points:
- We’ve designed a robust pipeline of products with brain penetration properties to address these key challenges,” said David Epstein, Ph.D., President and Chief Executive Officer of Black Diamond.
- In the first quarter of 2023, Black Diamond received allowance of its IND application from the FDA.
- Cash Position: Black Diamond ended 2022 with approximately $122.8 million in cash, cash equivalents, and investments compared to $209.8 million as of December 31, 2021.
- Net Loss: Net loss for the fourth quarter of 2022 was $21.1 million, as compared to $25.9 million for the same period in 2021.
Retrieved on:
Monday, February 27, 2023
and NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing novel MasterKey therapies targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023, at 12:50 p.m.
Key Points:
- and NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing novel MasterKey therapies targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023, at 12:50 p.m.
- ET in Boston, MA.
- A live webcast of the presentation can be accessed by visiting the investors relations section of the Company’s website at: www.blackdiamondtherapeutics.com .
- A replay of the webcast will also be available and archived for 90 days following the event.
Retrieved on:
Thursday, January 5, 2023
Key Points:
- CAMBRIDGE, Mass.
- and NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 9:00 a.m. PT in San Francisco, California.
- A live webcast of the presentation can be accessed by visiting the investors relations section of the Company’s website at: www.blackdiamondtherapeutics.com .
- A replay of the webcast will also be available and archived for 90 days following the event.
